Armata Pharmaceuticals

ARMPPhase 2

Los Angeles, United Statesarmatapharma.com

Armata Pharmaceuticals is focused on addressing the global antibiotic resistance crisis through its precision bacteriophage therapeutics, aiming to preserve the healthy human microbiome. The company has built a robust, in-house platform for phage discovery, engineering, and manufacturing, supporting a pipeline targeting multi-drug resistant pathogens like Pseudomonas aeruginosa and Staphylococcus aureus. Led by a seasoned team, including former White House Coronavirus Task Force coordinator Dr. Deborah Birx as CEO, Armata is positioning itself as a leader in the emerging phage therapy space.

Focus

BiologicsViral Technology

ARMP · Stock Price

USD 1400.004270.00 (-75.31%)

Historical price data

AI Company Overview

Technology Platform

A proprietary, fully integrated platform combining natural bacteriophage discovery with synthetic biology engineering to develop optimized, pathogen-specific phage therapeutics.

Pipeline Snapshot

13 drugs in pipeline

Drug	Indication	Stage
C16G2 Rinse + Placebo + C16G2 Gel	Dental Caries	Phase 2
AP-PA02	Non-cystic Fibrosis Bronchiectasis	Phase 2
C16G2 Strip	Dental Caries	Phase 2
C16G2	Dental Caries	Phase 2
C16G2 Gel	Dental Caries	Phase 2

Funding History

Total raised: $50M

PIPE$25MUndisclosedMar 15, 2021

IPO$15MUndisclosedOct 24, 2019

Series A$10MC3J TherapeuticsJun 15, 2015

Opportunities

The massive unmet need created by antibiotic-resistant infections represents a multi-billion dollar market.

Armata's precise phage therapy approach could gain rapid adoption in niche, life-threatening infections and expand into broader indications.

Its integrated manufacturing platform could also become a valuable asset for partnerships or contract services.

Risk Factors

The company faces significant clinical trial risk, regulatory uncertainty for a novel therapeutic class, and the constant need to raise capital as a pre-revenue entity.

Manufacturing complex phage cocktails at scale and competing in an emerging but increasingly crowded field are additional key challenges.

Competitive Landscape

Armata competes with other phage therapy developers (e.g., Adaptive Phage Therapeutics, Locus Biosciences) and companies pursuing novel antibiotic modalities. Its primary differentiation lies in its fully integrated, in-house capabilities for phage discovery, engineering, and GMP manufacturing, providing end-to-end control and potential speed advantages.